Trend
DailyDowntrend (confirmed)
4 hourBullish
1 hourExpanding
15 minStrong Bullish
5 minStrong Bullish
Daily trend turns up above $0.36
Key levels
Resistance$0.30
Resistance$0.25
Support$0.22
Latest news & SEC filings
EarningsContext Therapeutics Posts Q3 2026 Results, Gives Pipeline Update
EarningsContext Therapeutics posts smaller Q3 loss than analysts expected
All CNTX news →Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors. Its pipeline includes CTIM-76 targeting Claudin 6, CT-95 targeting Mesothelin, and CT-202 targeting Nectin-4. The company operates in the United States and holds global rights to develop and sell its product candidates.
Based on the company's 10-K filed Mar 23, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CNTX.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$1.04
12
Moat Score
NONE
1/9
Piotroski Score
-2.1
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
17.39%
FCF Growth YoY
-81.4%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for CNTX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:40:27 | $0.21 | 3,900 | $$824 | BUY |
| 21:39:30 | $0.21 | 4,400 | $$930 | BUY |
| 21:19:16 | $0.19 | 2,000 | $$381 | SELL |
| 21:06:22 | $0.22 | 3,000 | $$647 | BUY |
| 21:00:15 | $0.21 | 2,000 | $$424 | BUY |
5 dark pool trades shown · $$3K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Context Therapeutics Inc. (CNTX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Context Therapeutics Inc. (CNTX) is at $0.22, up 15.56% (+$0.03) at the Nov 11, 2026 close.
Latest CNTX news — Nov 11, 2026: Context Therapeutics Posts Q3 2026 Results, Gives Pipeline Update · Nov 10, 2026: Context Therapeutics posts smaller Q3 loss than analysts expected
Analyst ratings for CNTX: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
CNTX last reported on Aug 5, 2026: EPS -$0.15 vs -$0.09 expected — a miss of 62.9%.
CNTX does not currently pay a dividend.
Support: $0.22. Resistance: $0.25, $0.30, $0.36.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 11, 2026: Context Therapeutics Posts Q3 2026 Results, Gives Pipeline Update · Nov 10, 2026: Context Therapeutics posts smaller Q3 loss than analysts expected